Addex Spin-Out Neurosterix Wraps Phase 1 Of NTX-253 With Single And Multiple Ascending Dose Studies Providing Safety And Pharmacokinetic Data, Plans Phase 2 Schizophrenia Development

Loading news article.

Addex Spin-Out Neurosterix Wraps Phase 1 Of NTX-253 With Single And Multiple Ascending Dose Studies Providing Safety And Pharmacokinetic Data, Plans Phase 2 Schizophrenia Development | WAPE

Addex Spin-Out Neurosterix Wraps Phase 1 Of NTX-253 With Single And Multiple Ascending Dose Studies Providing Safety And Pharmacokinetic Data, Plans Phase 2 Schizophrenia Development

Article summary

Related companies

Analyzed by WAPE AI.

Comments —